KELLI THURMAN: Open Payments
NPI 1558357632 · BEDFORD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$973 in 43 payments from 14 companies in 2025. Trend: 2023 $1,117 · 2024 $1,023 · 2025 $973
Food & beverage: $973
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $251 |
| GENZYME CORPORATION | 4 | $138 |
| AstraZeneca Pharmaceuticals LP | 7 | $127 |
| Verona Pharma, Inc. | 3 | $70 |
| Insmed, Inc. | 3 | $63 |
| Vifor Pharma, Inc. | 2 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Grifols USA, LLC | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NUCALA, Ohtuvayre, Arikayce, FASENRA, Zemaira, GLASSIA.
Industry payments across TX — which companies pay providers there.
